YSYuanming Shen

Yuanming Shen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yuanming Shen has a total of 168 co-authors. Here are the top co-authors by number of shared publications:

  • Junfen Xu

    Department of Gynecologic Oncology, Women's Hospital Zhejiang University School of Medicine Hangzhou China

    20 shared publications
  • Weiguo Lu

    Department of Gynecologic Oncology, Women’s Hospital, Zhejiang University School of Medicine, Hangzhou, China

    20 shared publications
  • Sangsang Tang

    Women's Reproductive Health Laboratory of Zhejiang Province, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P.R. China

    18 shared publications
  • Kelie Chen

    Department of Toxicology of School of Public Health and Department of Gynecologic Oncology of Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China

    17 shared publications
  • Sen Li

    Women's Reproductive Health Laboratory of Zhejiang Province, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P.R. China

    17 shared publications
  • Weidong Fei

    Women's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China

    17 shared publications

Latest Publications

  • Open Access

    Camrelizumab combined with chemotherapy as postoperative adjuvant therapy after radical surgery for cervical cancer patients with pathologically positive lymph nodes: a prospective multicenter phase II clinical trial

    by Liqing Chen, Tingting Chen, Nalan Tu, Liya Dong, Yingli Zhang, Hui Wang, Yuanming Shen

    Chen L, et al. J Gynecol Oncol. 2027 ;38:e1. https://doi.org/10.3802/jgo.2027.38.e1

  • Open Access

    HRR gene promoter methylation-guided nomogram predicts PARP inhibitor efficacy and progression-free survival in high-grade serous ovarian cancer

    by Zhihua Zhou, Baoqin Ge, Tingting Chen, Shizhen Shen, Nalan Tu, Yuanming Shen

    Background: High-grade serous ovarian cancer (HGSOC) remains a lethal gynecologic malignancy with limited tools for accurately predicting PARP inhibitor (PARPi) efficacy. While promoter methylation of homologous recombination repair (HRR) genes is a potential biomarker, its clinical utility remains underexplored. This study aimed to systematically evaluate HRR gene promoter methylation profiles to predict PARPi sensitivity in HGSOC patients. Methods: We conducted a retrospective analysis of 96 HGSOC patients receiving PARPi maintenance therapy (olaparib or niraparib). The promoter methylation status of 12 HRR genes was quantitatively assessed via pyrosequencing. Patients were stratified into PARPi-sensitive and -insensitive groups based on OReO/ENGOT-ov38 criteria. Differential methylation sites were identified, lasso and multivariate logistic regression identified key methylation sites to construct a nomogram and a PARPi Resistance Score (PRS). PFS was analyzed by Kaplan‑Meier and Cox regression. Results: The PARPi-insensitive group exhibited significantly higher median methylation levels across HRR gene promoters compared to the sensitive group. Through rigorous screening, 12 CpG sites were consistently associated with PARPi response across subgroups. Through screening and LASSO regression, five CpG sites—ATM_Pos1, BRCA1(2S)_Pos2, BRCA2(1S)_Pos1, BRCA2(1S)_Pos7, and RAD51D_Pos6—were identified as independent predictors of PARPi sensitivity. The logistic model based on these five sites showed good discrimination, with area under the ROC curve (AUC) of 0.847 in the training set and 0.903 in the validation set; calibration and decision curve analysis supported clinical utility. Using the optimal PRS cutoff of − 1.023, High-PRS patients had significantly shorter median PFS (14 months vs. not reached; log‑rank P < 0.0001) and lower 12‑month PFS rate (52% vs. 97.2%). Multivariate Cox analysis confirmed PRS as the only independent prognostic factor for PFS (HR 4.85, 95% CI 2.31–10.20, P < 0.001). Conclusion: HRR gene promoter methylation, particularly at specific BRCA1, BRCA2 and RAD51D CpG sites, robustly predicts PARPi sensitivity and independently stratifies PFS in HGSOC patients. The nomogram and PRS provide clinically actionable tools for individualized PARPi therapy.

  • Open Access

    Efficacy of Fertility‐Sparing Treatment With Progestin Is Associated With Different Molecular Classification in Endometrial Carcinoma and Atypical Endometrial Hyperplasia

    by Xue‐Qian Qian, Hao‐Hui Fu, Xiao‐Yun Wan, Dong‐Xiao Hu, Yuan‐Ming Shen

    Objective: To investigate the impact of various molecular characteristics on the outcomes of fertility‐preserving therapy in patients with endometrial cancer (EC) and atypical endometrial hyperplasia (AEH). Methods: A total of 14 EC cases and 60 AEH cases were retrospectively analyzed at the Women's Hospital, Zhejiang University from January 2013 to October 2022. Results: This study investigated the molecular profiles and outcomes of fertility preservation in 74 cases. The most prevalent molecular profile was NSMP type (63.9%), followed by p53abn type (21.3%) and MMRd type (14.8%). After 6 months of progesterone therapy, the cumulative CR rates were 100% for NSMP type, 83.3% for MMRd type, and 33.3% for p53abn type ( p = 0.006). The CR rate in the p53abn group was significantly lower than in the other two groups ( p = 0.006), with a notably higher recurrence rate ( p = 0.006). ER and PR expression was significantly lower in the MMRd and p53abn groups ( p = 0.002). A total of 26 pregnancies (42.6%) were observed. In the EC group, the pregnancy rate of p53abn was lower than that of the NSMP group (0% vs. 83.3%, p = 0.02). In the AEH group, pregnancy rates of p53abn and MMRd were not significantly different from the NSMP group (0% vs. 50%, p = 0.16; 33.3% vs. 50%, p = 0.20). Conclusion: Molecular classification may serve as a predictive tool for the efficacy of fertility preservation therapy in patients with EC and AEH and was found to be particularly useful for identifying p53 mutants, which are associated with a high risk of recurrence, as well as MMRd types, which are known to lead to poor responses to progesterone treatment.


  • Open Access

    Pegylated liposomal doxorubicin plus carboplatin versus paclitaxel plus carboplatin as first-line therapy for epithelial ovarian cancer (CGCS-04): a multicenter, randomized clinical trial

    by Yuanming Shen, Nalan Tu, Beihua Kong, Bairong Xia, Yonghui Zou, Rutie Yin, Qingshui Li, Ying Yue, Shan Kang, Ke Wang, et al.

    Background: The current standard-of-care chemotherapy for treatment-naïve epithelial ovarian cancer is paclitaxel plus carboplatin. Objectives: To compare the efficacy and safety of pegylated liposomal doxorubicin (PLD) plus carboplatin versus paclitaxel plus carboplatin as first-line treatment in patients with epithelial ovarian cancer. Design: This was an investigator-initiated, multicenter, open-label, randomized, noninferiority trial. Methods: This trial with a prespecified noninferiority margin (HR 0 ) of 1.2, was conducted in 20 clinic centers in China. Eligible patients were randomly assigned in a 1:1 ratio to receive either PLD (30 mg/m 2 on day 1) plus carboplatin (area under the curve (AUC) 5 on day 1; experimental group) or paclitaxel (175 mg/m 2 on day 1) plus carboplatin (AUC 5 on day 1; control group) for up to six cycles. The primary endpoint was progression-free survival (PFS). The key secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety. Results: Between March 21, 2019, and December 8, 2021, 395 eligible patients were enrolled, of whom 195 were randomly assigned to receive PLD-carboplatin and 196 received paclitaxel-carboplatin. Median PFS was 35.3 months (95% confidence interval (CI), 23.7–46.9) in the experimental group and 35.0 months (95% CI, 26.9–43.1) in the control group (hazard ratio = 0.99, 95% CI, 0.73–1.35; p = 0.94). There were no statistically significant differences between the two groups in median ORR (80.5% vs 79.2%), DCR (90.2% vs 83.3%), 2-year OS rate (96.2% vs 92.4%), or 4-year OS rate (87.6% vs 82.4%; all p > 0.05). In the experimental and control groups, 165 (84.6%) and 169 (86.2%) patients experienced at least one adverse event (AEs). Alopecia (9.2% vs 28.1%, p < 0.001), peripheral sensory neuropathy (2.1% vs 17.9%, p < 0.001), and febrile neutropenia (1.0% vs 6.1%, p = 0.01) were less common in the PLD-carboplatin group compared to the paclitaxel-carboplatin group. Conclusion: The superior tolerability and comparable efficacy of PLD plus carboplatin over paclitaxel plus carboplatin as a first-line treatment for epithelial ovarian cancer suggest that substituting paclitaxel with PLD is both feasible and potentially more beneficial. Trial registration: This trial is registered with ClinicalTrials.gov, NCT03794778.


  • Open Access

    CSN5 overexpression promotes the integral progression of cervical cancer by enhancing ENO3-mediated glycolysis

    by Zhu Cao, Shizhou Yang, Jian Zou, Ye Jin, Yanan Zhang, Tingting Chen, Yuanming Shen

    Cervical cancer (CC) remains a significant global health challenge. A deeper understanding of the molecular mechanisms driving CC progression is crucial for developing improved therapeutic strategies. CSN5 is vital in cell functions and cancer, but its role in CC is unclear. This study aims to explore CSN5’s role and its target gene in CC progression, assessing their potential as therapeutic targets. We employed an integrated approach combining bioinformatics analysis, proteomic profiling, and in vitro and in vivo functional assays. Immunohistochemistry was used to analyze CSN5 and ENO3 expression in CC and normal tissues. CSN5 upregulation was associated with advanced clinical stage and poor differentiation. Furthermore, CSN5 overexpression enhanced cellular proliferation and glycolytic metabolism but, paradoxically, suppressed migration, invasion, and the epithelial-mesenchymal transition (EMT). These pro-tumorigenic effects were confirmed in vivo, and the glycolytic inhibitor 2-DG was found to reverse the phenotypes induced by CSN5. Protein sequencing highlighted ENO3’s role in CSN5-mediated tumorigenesis, regulating EMT and glycolysis by stabilizing its ubiquitination degradation through CSN5. Crucially, silencing ENO3 attenuated the oncogenic effects of CSN5 both in vitro and in vivo. Our findings unveil a novel mechanistic paradigm in which CSN5 promotes CC progression by co-opting ENO3 to enhance glycolytic flux while concurrently suppressing cell motility. This study not only deepens the understanding of CC pathogenesis but also identifies the CSN5-ENO3 axis as a promising target for novel therapeutic interventions. Graphical abstract


  • Open Access

    Clinical utility of HRR gene methylation for predicting PARPi sensitivity in HGSOC patients

    by Zhihua Zhou, Baoqin Ge, Tingting Chen, Shizhen Shen, Nalan Tu, Yuanming Shen

    Objective To develop a methylation-based predictive model for PARP inhibitor (PARPi) efficacy in advanced high-grade serous ovarian cancer (HGSOC) patients. Design Retrospective analysis of tumor tissues from 96 advanced HGSOC patients receiving PARPi maintenance therapy (78 sensitive, 18 insensitive). Setting A tertiary gynecologic oncology center at Women’s Hospital, Zhejiang University School of Medicine, China. Population or Sample 96 advanced HGSOC patients receiving PARPi maintenance therapy. Methods Pyrosequencing assessed methylation levels across promoter regions of 10 HRR genes. A nomogram prediction model was constructed using LASSO regression to identify key methylation sites associated with PARPi sensitivity in a training cohort (n=68) and validated in an independent cohort (n=28). Performance was compared to conventional BRCA/HRD testing. Main Outcome Measures PARPi sensitivity prediction accuracy measured by AUC of ROC curves and comparison with BRCA/HRD testing. Results 93 of 96 methylation sites showed significantly lower median methylation levels in PARPi-sensitive patients (pConclusions HRR gene promoter methylation, particularly PALB2, RAD51D, and CHEK2, is a potent predictor of PARPi efficacy in HGSOC. The nomogram provides a robust clinical tool outperforming standard BRCA/HRD testing.

  • Human Papillomavirus Genotype Attribution and Integration in High-Grade Vaginal Intraepithelial Neoplasia

    by Yuanming Shen, Sangsang Tang, Yumei Zhou, Qiuxue Zhang, Tingting Chen, Jingnan Li, Yu Wang, Xiaoyun Wan, Weiguo Lu, Junfen Xu

    Objective: The aim of the study was to investigate the distribution and association between human papillomavirus (HPV) genotypes and integration as well as their correlation with cervical lesions. Methods: Two hundred seven patients diagnosed with high-grade vaginal intraepithelial neoplasia (HG-VaIN) were recruited from the Women's Hospital School of Medicine Zhejiang University between 2015 and 2021 and assayed for HPV genotyping. HPV integration sequencing analysis was conducted using tissues from 53 patients with HG-VaIN and 4 patients with invasive vaginal carcinoma (IVC), along with paired cervical lesion specimens. Results: A total of 207 patients with HG-VaIN were categorized as having cervical lesions unrelated to HG-VaIN (group A, 71 patients, 34.30%) or cervical lesion-related HG-VaIN (group B, 136 patients, 65.70%). With an average follow-up of 42.19 months, 12 of 153 patients progressed to IVC and were all from group B. HPV16 infection and the presence of cervical lesions were the 2 main factors associated with disease progression, with cervical lesion coexistence being an independent factor. Compared with group A (5/20, 25%), group B (17/33, 51.52%) showed a higher rate of HPV integration, as demonstrated using HPV integration sequencing analysis, with HPV16 being the most integrated genotype (72.73%). The integration analysis of 4 patients with IVC paired with cervical lesion specimens showed that 3 of the 4 pairs exhibited the same HPV infection and integration sites, indicating a high degree of homology in HPV integration between cervical lesions and HG-VaIN-induced IVC. Conclusions: Patients with HG-VaIN associated with cervical lesions exhibited a higher risk of malignant transformation, necessitating more proactive treatment approaches.


  • Open Access

    Comparison of the safety between conization and hysterectomy for patients with cervical adenocarcinoma in situ

    by Jingjing Liu, Yu Wang, Xiaoyun Wan, Jian Zou, Yedan Zhu, Jiashan Zou, Weiguo Lu, Xing Xie, Yuanming Shen

    Objective: To compare the safety between conization alone and hysterectomy for patients with adenocarcinoma in situ (AIS) of the cervix. Design: A cohort study of AIS patients during 2007-2021. Setting: Women’s Hospital of Zhejiang University School of Medicine. Population: A total of 453 AIS patients diagnosed by conization who underwent cervical conizations only (n=153) or conization followed by hysterectomy(n=300). Methods: The clinicopathological and follow-up data were reviewed. Univariate analysis was examined by chi-square test and multivariate analysis was performed by logistic regression analysis. Main outcome measure: The rates of residual disease in specimens of hysterectomy and repeated conization were compared between positive and negative margin of conization. And the rates of recurrence were compared between patients treated by conization(s) alone and hysterectomy. The factors influencing residual disease and recurrence were assessed, respectively. Results: Among 310 specimens of hysterectomy or repeated conization, the rates of residual disease were 50.56% (45/89) for positive margin and 2.26% (5/221) for negative margin, with a significant difference (p=0.000). Totally 4 patients recurred as vaginal intraepithelial neoplasia(VAIN)in those treated by hysterectomy and 1 recurred as cervical squamous intraepithelial neoplasia (CIN) in those treated by conization(s) alone. The rates of recurrence were 0.65% (1/153) for conization(s) alone and 1.33 % (4/300) for hysterectomy, with no significant difference (p=0.431). Hysterectomy was a factor influencing neither residual disease nor recurrence. Conclusions: Conization is an effective and safe option for patients with AIS of the cervix, provided the margin is negative. Keywords: adenocarcinoma in situ, conization, hysterectomy, margins.

  • Open Access

    Evaluation of the prognostic value of lymphadenectomy in low-grade serous ovarian cancer: A case-control multicenter retrospective study

    by Zhongshao Chen, Ran Chu, Yuanming Shen, Qin Yao, Tianyu Qin, Li Li, Gang Chen, Chaoyang Sun, Li Song, Junting Li, et al.

    Objective: To evaluate the effect of lymphadenectomy on clinical outcome in patients with low-grade serous ovarian cancer (LGSOC). Design: Case-control multicenter retrospective study. Setting: University Hospital-based research center. Population: 147 patients with LGSOC. Methods: Propensity score matching (PSM) algorithm was used to balance the basic characteristics of patients with lymphadenectomy or not, and the Kaplan-Meier analysis was used to evaluate the impact of clinical prognosis. Finally, univariate and multivariate Cox proportional hazards regression analysis were performed to analyze the high-risk factors associated with clinical prognosis. Main outcome measures: Disease-free survival (DFS) and overall survival (OS). Results: A total of 147 women from 4 medical centers were enrolled. In the before matching cohort, 101 (68.7%) patients underwent lymphadenectomy. Fifty-two (35.4%) patients experienced recurrence, and 25 (17%) patients died. Kaplan-Meier analysis showed that there was no significant difference in DFS(P=0.058) and OS(P=0.067) in the after matching cohort. Cox proportional hazard regression analysis showed age (P=0.012), the International Federation of Gynecology and Obstetrics (FIGO) stage (P=0.031) and effective cytoreductive surgery (P=0.044) were 3 high-risk factors associated with recurrence. Age (P=0.031) and effective cytoreductive surgery (P=0.009) were 2 high-risk factors associated with death. Conclusions: Lymphadenectomy seems not to provide a significant benefit neither DFS nor OS in our study. Age, the FIGO stage and effective cytoreductive surgery are high-risk factors associated with clinical prognosis in LGSOC patients.